Star Trek: Phase II

InvestmentPitch Media Video Discusses Inflection Resources’ Signing of Non-Binding Heads of Agreement with AngloGold Ashanti for Multi-Year Exploration Earn-In Across Portfolio of Copper-Gold Projects in Australia

Retrieved on: 
Friday, February 24, 2023
AngloGold Ashanti, III, News, Inflection, Gold, Phase II, CSE, Lachlan Fold Belt, Evolution, AUD, Agreement, Star Trek: Phase II, Duck Creek, Mining, Pharmaceutical industry, Northparkes

If these links are not enabled, please visit www.InvestmentPitch.com and enter “Inflection” in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Inflection” in the search box.
  • Following execution of the Earn-in Agreement, AngloGold shall fund a total of AUD$10 million on exploration expenditures across the portfolio of projects within three years as part of a Phase I exploration program.
  • Alistair Waddell, President and CEO, stated: “The execution of this Heads of Agreement with AngloGold Ashanti is a major milestone for the Company.
  • We fully anticipate recommencing drilling immediately following the execution of the Earn-in Agreement, all of which will now be fully funded by AngloGold.

DARPA Awards Duality Technologies Multimillion Dollar Contract to Accelerate Machine Learning on Encrypted Data

Retrieved on: 
Tuesday, January 10, 2023
Email encryption, Partnership, Government, ML, Research, Department of Defence, Organization, United States Department of Defense, Star Trek: Phase II, DARPA, Privacy, Privacy and the US government, Machine learning, Interview, Unitary state, FHE, Data science, Satellite navigation device, Duality

HOBOKEN, N.J. , Jan. 10, 2023 /PRNewswire/ -- Duality Technologies, the leader in privacy preserving data collaboration, today announced that the company was selected for Phase II of the DARPA Data Protection in Virtual Environments (DPRIVE) program. New capabilities for accelerated privacy-protected machine learning developing in the project will be integrated into Duality Technology's secure data collaboration platform, offering customers the most comprehensive ability to apply data science and machine learning on sensitive data in an expedient and collaborative way that further breaks down data silos that exist within and between organizations.

Key Points: 
  • New capabilities for accelerated privacy-protected machine learning developing in the project will be integrated into Duality Technology's secure data collaboration platform, offering customers the most comprehensive ability to apply data science and machine learning on sensitive data in an expedient and collaborative way that further breaks down data silos that exist within and between organizations.
  • This leading open source FHE software library revolutionizes computation on encrypted data - ensuring data security to address applications for the US Government, Department of Defense (DoD) and in commercial applications.
  • In Phase I, the Duality-led team designed a hardware accelerator for machine learning on data encrypted using FHE.
  • The team's successful design work in Phase I justified their selection for Phase II and the multimillion dollar research and development contract to design and prototype encrypted computing acceleration hardware.

Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

Retrieved on: 
Monday, October 3, 2022
Health, Genetics, Other Health, Other Science, Research, Science, Maintenance, European Regional Development Fund, ERDF, IFOP, Commercial Operating System (COS), AMF, American Heart Association, Trial of the century, Marketing, Time, LDL, Research and development, Degenerative disease, ICO, BPI, Gene, Blood, Health, Population, Cholesterol, Investor, BARD, Metabolomics, AHA, Teaching hospital, Phase, HEART, Bacteria, Institute, Industrial Affairs Committee (Iceland), Development, Volunteering, Director, Union, Patient, Hypercholesterolemia, Biochemistry, Metabolism, Risk, Board, Research, Company, Star Trek: Phase II, Pharmaceutical industry, Legume, Dietary supplement, Risk management

Valbiotis (FR0013254851 ALVAL, PEA/SME eligible)(Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, presents additional positive results from the Phase II HEART clinical study with TOTUM070 for hypercholesterolemia.

Key Points: 
  • Valbiotis (FR0013254851 ALVAL, PEA/SME eligible)(Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, presents additional positive results from the Phase II HEART clinical study with TOTUM070 for hypercholesterolemia.
  • The Phase II HEART clinical study was a multi-center, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated mild to moderate LDL hypercholesterolemia.
  • At the hepatic level, the clinical mode of action study, which had previously reported positive results ( press release of March 29, 2022 ), has delivered additional results at the molecular level2.
  • Murielle CAZAUBIEL, Director of Medical, Regulatory and Industrial Affairs and member of the Valbiotis Board of Directors, comments: "The additional clinical efficacy results from the HEART study are excellent for TOTUM070.

 Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Pharmaceutical, Health, Institute, Mission statement, Prediabetes, Degenerative disease, Volunteering, Health, IFRS, Time, United Nations Global Compact, De novo, ESG, Hypercholesterolemia, Development, LDL, Statutory auditor, Director, Risk, Corporate social responsibility, Phase, Research, NASH, Small, Nutrition, Russell Midcap Index, Company, Population, Pernod Ricard, Review, Non-alcoholic fatty liver disease, Partnership, CSR, Food science, Environment, Program, Star Trek: Phase II, Physician, Université Laval, Triglyceride, Research and development, Liver, Board, Christofle, INAF, Marketing, Awareness, ISO, Dysglycemia, INSIGHT, Pharmaceutical industry, Dietary supplement

In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).

Key Points: 
  • In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).
  • In February 2022, Valbiotis received approval to initiate two Phase II/III clinical trials, INSIGHT and INSIGHT 2 ( press release of February 17, 2022 ).
  • The Company's interim financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 7, 2022.
  • They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com (investors section).

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment

Retrieved on: 
Tuesday, September 6, 2022
Technology, Pain, OA, Swelling, Man, Conditional sentence, Injection, Science, Osteoarthritis, Job, U.S. Securities and Exchange Commission, Method, Anterior cruciate ligament, GLOBE, Leadership, Twitter, Adult, Patient, Inflammation, Berlin Institute for Population and Development, Investor, Knee, Engineering, Regeneration, PLUR, Disability, European, Center, Arthritis, Nasdaq, Woman, Climate change, Industry, Ministry of Education (Malaysia), Trial of the century, Security (finance), Legislation, Disease, Solution, Pressure, LinkedIn, Homeostasis, Quality of life, Star Trek: Phase II, TASE, Private Securities Litigation Reform Act, Israel Innovation Authority, Health, Mortality, Chronic pain, HIV disease progression rates, Regenerative medicine, Phase, Knowledge, Pharmaceutical industry, Plural

The goal of the PROTO project is to utilize Pluris PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).

Key Points: 
  • The goal of the PROTO project is to utilize Pluris PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).
  • Professor Winkler was also the lead PI in the Phase II and Phase III muscle regeneration studies using Pluris PLX-PAD cells.
  • Having evaluated PLX-PAD in other advanced-stage clinical studies, we see clear potential for this cell-based product to treat OA, Professor Winkler said.
  • This award underscores the vast potential of our PLX-PAD cells to treat chronic disease with regenerative medicine, said Yaky Yanay, Pluris CEO and President.

Astra Exploration completes Phase II drilling and Extends Pacienca Vein to 2.1km with Assays Expected in September

Retrieved on: 
Tuesday, August 23, 2022
Astra, RC, View, ASTR, Tormenta, Time, Star Trek: Phase II, Risk, Phase, Vein, Multimedia, Company, WNW, News, Failure, Paciência, Private Securities Litigation Reform Act, Acquisition, Industry, LSE, Marketing, Mission statement, Quartz, Uranium, Mining, COVID-19, BC

The Phase II program consisted of 3,976 metres of RC drilling in 15 holes, all in the North Zone target area (Figure 1).

Key Points: 
  • The Phase II program consisted of 3,976 metres of RC drilling in 15 holes, all in the North Zone target area (Figure 1).
  • The primary focus was to test the Paciencia Vein System at depth in the two defined high-grade zones defined earlier this year in the Phase I drill program (Figure 2).
  • Eleven holes were drilled into known veins, with 4 holes directed to Paciencia Oeste vein segment, 3 to Paciencia and 4 to Paciencia Este segment.
  • Some deeper holes in the Paciencia and Paciencia Este vein segments are showing a change in the dip and thickness of the vein.

Atlantic Biomass, LLC and Bionoid, Inc. Sign Letter of Intent to Produce Commercial Quantities of Sustainable Aviation Fuels (SAF) from Residual Hemp Biomass

Retrieved on: 
Thursday, August 11, 2022
UMES, HBCU, Income, CEBA, Ohio State University, Letter, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Biomass, Growth, Investment, USD, LLC, Intention, Eastern Shore of Maryland, Small business, SAF, Bioproducts, University of Maryland Eastern Shore, IFP, Maryland House of Delegates, LOI, CBD, Hood College, GHG, Environmental biotechnology, Goal, Genetics, Rubber industry in Malaysia, University, Star Trek: Phase II, Biofuel, Interstate 95 in Maryland, Health, Greenhouse gas, Renewable energy, List of Advanced Dungeons & Dragons 2nd edition monsters, Food

FREDERICK, Md., Aug. 11, 2022 /PRNewswire-PRWeb/ -- In a surprise announcement at the annual Advisory Board Meeting of the Maryland Energy Innovation Institute (MEI2), Phase I MEI2 grant recipient Atlantic Biomass, LLC signed a Letter of Intent with Bionoid, Inc. signaling their joint commitment to producing commercial quantities of Sustainable Aviation Fuels (SAF) from residual hemp biomass.

Key Points: 
  • This LOI will lead to the production of SAF and other bioproducts from up to 190,000 tons of annual residual hemp biomass harvests.
  • "This agreement with Bionoid launches us on the commercial pathway we need," said Atlantic Biomass President Bob Kozak.
  • Atlantic Biomass, LLC, a small business located in Frederick, Maryland is focused on the development and commercialization of proprietary enzymatic based biomass "deconstruction" processes.
  • These processes allow the use of low-cost, non-food biomass as feedstocks for renewable sustainable biofuels and bioproducts.

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
IMM, Australian Securities Exchange, Oral, Company, Immunotherapy, Population, Annual general meeting, 2021 Essex County Council election, Patient, NASDAQ, APC, Antibody, Phase, ORR, Central Time Zone, Society, ASX, NSCLC, Immutep, Pembrolizumab, Large-cell lung carcinoma, Infection, Star Trek: Phase II, LAG-3, Autoimmune disease, Technology, CDT, Endpoint security, ASCO, PD, Cancer, GLOBE, Pharmaceutical industry, Online shopping

Data from the trial will be presented in an Oral Presentation on 3 June 2022.

Key Points: 
  • Data from the trial will be presented in an Oral Presentation on 3 June 2022.
  • Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that will be presented as a Trial-in-Progress Poster Presentation at ASCO 2022.
  • Similarly, the presentations will be available at the times indicated below on ASCO.org and subsequently made available on Immuteps website.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Canc

Retrieved on: 
Thursday, April 28, 2022
Star Trek: Phase II, Metastasis, INCA, INSERM, Purging disorder, Medication, Colorectal cancer, National Agency for Food and Drug Administration and Control, The True Cost, Fatigue, Death, III, Oncology, Patient, Blood, Risk, GLOBE, American Cancer Society, Large intestine, Connective tissue, Cancer, Anxiety, Neoplasm, Technology, Quality of life, Forward-looking statement, Immunohistochemistry, Oxaliplatin, Trifluridine/tipiracil, Fluoropyrimidine, Dijon, Achievement, Antibody, Serum, Research, Terminology, VEGF, NASDAQ, Safety, Phase, Industry, SEC, National Cancer Institute, ANSM, Survival, Disease, Irinotecan, Pharmaceutical industry, Vaccine

The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study.

Key Points: 
  • The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study.
  • Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.
  • Headed by Dr. Franois Ghiringhelli and Dr. Come Lepage, the clinical program will include over 20 participating clinical centers and enroll at least 160 subjects.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Retrieved on: 
Monday, September 27, 2021
Desire, Star Trek: Phase II, News, Post-traumatic stress disorder, Health minister, Trauma, Distress, Man, University, Instagram, Clinical Obstetrics and Gynecology, Desire Projects, Solution, Moses Austin, III, CSE, Professor, MDMA, LinkedIn, Adult, Manifest and latent functions and dysfunctions, Phrase, Twitter, FRA, CEO, Gynaecology, Company, MAPS, Woman, Female, Fear, Obstetrics, Mental health, Social behavior, COVID-19, Hypoactive sexual desire disorder, Psychiatry, Research, PTSD, Laboratory, Psychotherapy, Theology, HSDD, Department, Birth control, Pharmaceutical industry, Risk management

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."